WASHINGTON (December 19) –   Today, the Center for Medicare and Medicaid Innovation (CMMI) announced a proposed series of Medicare drug pricing demonstrations affecting some Part B  and Part D  medicines, respectively. The Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) demonstrations would significantly restructure Medicare drug reimbursement and coverage, pegging Medicare Part B and Part D drug prices to those

WASHINGTON ( December 2 ) -- Yesterday, the United States and the United Kingdom announced  a new agreement on pharmaceutical pricing as part of the Economic Prosperity Deal (EPD). The agreement is expected to increase the U.K.'s valuation of new medicines and expand its long-term investment in innovative therapies. The United States, in turn, committed to exempt U.K.-origin pharmaceuticals from any future Section 232 tariffs and to refrain from targeting U.K. pricing polici

WASHINGTON ( Sep 30 ) -- Today, the Trump administration announced its first agreement with a manufacturer to bring most-favored-nation...

WASHINGTON, D.C. ( July 31 ) -- Today, the Trump administration announced  a 60-day deadline for 17 leading pharmaceutical manufacturers...

On June 24, Incubate executive director John Stanford joined Punchbowl News for a discussion  on the future of medicine. The culmination...

The White House and some members of Congress have recently proposed  adopting a "Most Favored Nation"   (MFN) pricing model for Medicaid...